CSIMarket
 
Structure Therapeutics Inc   (NASDAQ: GPCR)
Other Ticker:  
 
 
Price: $30.7000 $0.75 2.504%
Day's High: $31.33 Week Perf: 1.25 %
Day's Low: $ 30.15 30 Day Perf: 10.59 %
Volume (M): 435 52 Wk High: $ 62.74
Volume (M$): $ 13,361 52 Wk Avg: $37.90
Open: $30.35 52 Wk Low: $23.50



 Market Capitalization (Millions $) 5,269
 Shares Outstanding (Millions) 172
 Employees 86
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -111
 Cash Flow (TTM) (Millions $) 121
 Capital Exp. (TTM) (Millions $) 2

Structure Therapeutics Inc
Structure Therapeutics Inc is a biotechnology company focused on discovering and developing small molecule drugs to target RNA structures implicated in various diseases. The company's research and development efforts are centered around the understanding of RNA structure and how it relates to disease pathways. By targeting specific RNA structures, Structure Therapeutics aims to develop innovative therapies that can effectively regulate gene expression and treat diseases such as cancer, genetic disorders, and viral infections. The company utilizes a combination of computational tools, high-throughput screening, and medicinal chemistry to identify and optimize small molecules that can modulate these RNA structures. Structure Therapeutics aims to provide novel therapeutic options that can address unmet medical needs and improve patient outcomes.


   Company Address: 601 Gateway Blvd. South San Francisco 94080 CA
   Company Phone Number: 457-1978   Stock Exchange / Ticker: NASDAQ GPCR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        5.24% 
BMY   -2.64%    
JNJ        1.05% 
LLY        6.9% 
MRK   -10.19%    
PFE   -2.39%    
• View Complete Report
   



Clinical Study

Evaluating the Therapeutic Progression of Structure Therapeutics ACCG-2671s Promising Profile and Financial Insights

Published Sun, Dec 29 2024 10:19 AM UTC

The effective management of obesity remains a daunting challenge in pharmacotherapy, amidst rising prevalence rates and associated comorbidities. Structure Therapeutics Inc. has recently advanced its developmental pipeline with the announcement of its lead oral small molecule amylin receptor agonist, ACCG-2671, targeting the treatment of obesity. This article elucidates the ...

Clinical Study

Advancements in Obesity Management Phase 2b ACCESS Study for GSBR-1290 Demonstrates Promising Potential

Published Wed, Nov 13 2024 9:01 PM UTC

AbstractThe rising prevalence of obesity has necessitated the development of effective pharmacological interventions. Structure Therapeutics oral small molecule GLP-1 receptor agonist, GSBR-1290, is currently under investigation in the Phase 2b ACCESS clinical study aimed at evaluating its efficacy and safety over a 36-week period. Preliminary results from earlier Phase 2a...

Product Service News

Structure Therapeutics Inc. Announces Key Leadership Changes to Propel Development of Novel Therapeutics

Published Tue, Sep 17 2024 8:05 PM UTC

Abstract: Structure Therapeutics Inc., a clinical-stage global biopharmaceutical firm focused on developing innovative oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced significant leadership changes aimed at enhancing operational efficiency and advancing its drug development programs. On September 17, 2024, Structure Therapeutics I...

Financing Agreement

Structure Therapeutics Inc. Raises $547.4 Million in Public Offering, Faces Quick Ratio Challenges

Published Fri, Jun 7 2024 8:05 PM UTC

Structure Therapeutics Inc. recently announced the successful closing of its upsized underwritten public offering, which saw the sale of 10,427,017 American depositary shares (ADSs) at a price of $52.50 per ADS. This resulted in aggregate gross proceeds of approximately $547.4 million for the company.
However, despite a sequential decrease in current liabilities, the co...

Stock Market Announcement

Structure Therapeutics Announces Successful Pricing of Upsized $476 Million Public Offering amidst Encouraging Market Performance

Published Wed, Jun 5 2024 11:54 PM UTC



San Francisco-based biopharmaceutical company, Structure Therapeutics Inc., recently unveiled the pricing details of its upsized underwritten public offering. The offering, comprising 9,066,972 American depositary shares (ADSs) at a price of $52.50 per ADS, is predicted to generate approximately $476.0 million in gross proceeds for the company. Furthermore, an opti...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com